Science · 3 sources covering this

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

The trial ‌will evaluate Mapp Biopharmaceutical's experimental MBP134 antibody as a standalone treatment for Bundibugyo Ebola, as well as in combination with Gilead Sciences' antiviral drug remdesivir, the WHO said

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

3 L · 0 C · 0 R

How 3 sources are covering this

The HinduLean L·2h ago
Trial for Bundibugyo Ebola treatment starts in DRC, WHO says
The trial ‌will evaluate Mapp Biopharmaceutical's experimental MBP134 antibody as a standalone treatment for Bundibugyo Ebola, as well as in combination with Gilead Sciences' antiviral drug remdesivir, the WHO said
Read at The Hindu →
The HinduLean L·

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/bd167e1102b7f7dcb8023e07302b94b2322c3163"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Trial for Bundibugyo Ebola treatment starts in DRC, WHO says"></iframe>

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

How 3 sources are covering this

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

More from Science

Health groups demand overhaul of India’s essential medicines list

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

Trial for Bundibugyo Ebola treatment starts in DRC, WHO says

Indian scientists recreate key functions of human Placenta on chip

Centre’s intervention to stabilise Andhra mango sector | Explained

Why diagnosing TB in children continues to be a challenge in India

Reader

Trust & legal

Across the network